Skip to main content
SpringerLink
Log in

Treatment of Endocrine Gastroenteropancreatic Tumors with Somatostatin Analogues

  • Conference paper
Book cover Peptides in Oncology III

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 153))

Abstract

Somatostatin is a hormone that regulates the function of several exocrine and endocrine glands. The peptide mediates its actions via five different receptors. These proteins are expressed in a tissue-specific manner. Somatostatin receptors are also present in neuroendocrine gastroenteropancreatic tumors. Two long-acting somatostatin analogues, octreotide and lanreotide, are recognized by the receptor subtypes 2 and 5. Excessive hormone secretion in carcinoid syndrome can be controlled by these drugs. In addition, at least a subgroup of patients with carcinoid syndromes respond with delayed tumor growth during octreotide therapy. In the future, the availability of the somatostatin receptor cDNAs will allow the development of specific and even more potent receptor analogues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Arnold R, Frank M (1995) Systemic chemotherapy for endocrine tumors of the pancreas: recent advances. In: Mignon M, Jensen RT (eds) Endocrine tumors of the pancreas. Karger, Basel, pp 431–438

    Google Scholar 

  • Arnold R, Frank M (1996) Gastrointestinal endocrine tumors: medical management. Baillieres Clin Gastroenterol 10:737–759

    Article  PubMed  CAS  Google Scholar 

  • Arnold R, Neuhaus C, Benning R, Schwerk WB, Trautmann ME, Joseph K, Bruns C (1993) Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17: 511–519

    Article  PubMed  CAS  Google Scholar 

  • Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38: 430–438

    Article  PubMed  CAS  Google Scholar 

  • Boden G (1989) Glucagonomas and insulinomas. Gastrenterol Clin North Am 18:831–847

    CAS  Google Scholar 

  • Boden G, Ryan IG, Eisenschmidt BL, Shelmet JJ, Owen OE (1986) Treatment of inoperable glucagonoma with long-acting somatostatin analogue SMS 201–995. N Engl J Med 314: 1686–1689

    Article  Google Scholar 

  • Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guilleman R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79

    Article  PubMed  CAS  Google Scholar 

  • Clements D, Elias E (1985) Regression of metastatic VIPoma with somatostatin analogue SMS 201–995. Lancet 1:874–875

    Article  PubMed  CAS  Google Scholar 

  • de Lecea L, Criado JR, Propero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, Dunlop CLM, Siggins GR, Nenrksen SJ, Sutcliffe JG (1996) A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381: 242–245

    Article  PubMed  Google Scholar 

  • Fehmann HC; Arnold R (1996) Molekularbiologie, Pharmakologie uns Signal transduktion der fünf klonierten humanen Somatostatin Rezeptoren1. Z Gastroenterol 34:767–774

    CAS  Google Scholar 

  • Frankton S, Bloom SR (1996) Glucagonomas. Baillieres Clin Gastroenterol 10:697–705

    Article  PubMed  CAS  Google Scholar 

  • Fukusumi S, Kitada C, Takekawa S, Sakamoto M, Miyamoto M Hinuma S, KItano K, Fujino M (1997) Identification and characterization of a novel human cortistatin-like peptide. Biochem Biophys Res Commun 232: 157–163

    Article  PubMed  CAS  Google Scholar 

  • Harris AG, Redfern JS (1995) Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Aliment Pharmacol Ther 9: 387–394

    Article  PubMed  CAS  Google Scholar 

  • Jais P, Terris B, Ruszniewski P, Le Romancer M, Reyl-Desmars F, Vlssuzaine C, Cadiot G, Mignon M, Lewin MJM (1997) Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 27:639–644

    Article  PubMed  CAS  Google Scholar 

  • John M, Meyerhof W, Richter D (1996) Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38: 33–39

    Article  PubMed  CAS  Google Scholar 

  • Jonas S, John M, Boese-Landgraf J (1995) Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues. Langenbecks Arch Chir 380: 90–95

    Article  PubMed  CAS  Google Scholar 

  • Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M Tsuda K, Imura H, Seine S, Seino Y (1995) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors. J Clin Invest 93: 1321–1325

    Article  Google Scholar 

  • Lamberts SWJ, Lely AJ, Herder WW, Hofland L (1996) Octreotide. N Engl J Med 334:246–254

    Article  PubMed  CAS  Google Scholar 

  • Montminy MR, Goodman RH, Horovitch SJ, Habener JF (1984) Primary structure of the gene encoding rat prosomatostatin. Proc Natl Acad Sci USA 81:3337–3340

    Article  PubMed  CAS  Google Scholar 

  • Patel Y, Srikant CB (1995) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTRl-5). Endocrinology 135:2814–2817

    Article  Google Scholar 

  • Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW (1997) Activation in vitro of somatostatin receptor subtypes 2, 3 or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected ras transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol 11: 1062–1069

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Häcki W, Lamberts SWJ (1987) Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 65: 1127–1134

    Article  PubMed  CAS  Google Scholar 

  • Reubi JC, Schaer JC, Waser B, Mengod G (1994) Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 54: 3455–3459

    PubMed  CAS  Google Scholar 

  • Ruszniewski P, Ducreux M, Chayvialle JA (1996) Treatment of carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39: 279–283

    Article  PubMed  CAS  Google Scholar 

  • Saltz L, Trochanowsky G, Buckley M, Heffernan B, Niedzwicki D, Tao Y, Kelsen D (1993) Octreotide as an anti-neoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 72: 244–248

    Article  PubMed  CAS  Google Scholar 

  • Scarpignato C (1995) Somatostatin analogues in the management of endocrine tumors of the pancreas. In: Mignon M, Jensen RT (eds) Endocrine tumors of the pancreas. Karger, Basel, pp 385–414

    Google Scholar 

  • Schaer JC, Waser B, Mengod G, Reubi JC (1997) Somatostatin receptor subtypes sstl, sst2, sst3, sst4, sst5 expression in human pituitary, gastroenteropancreatic and mammary tumors: comparison of MRNA analysis with receptor autoradiography. Int J Cancer 70: 530–537

    Article  PubMed  CAS  Google Scholar 

  • Sharma K, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10: 1688–1696

    Article  PubMed  CAS  Google Scholar 

  • Shepherd JJ, Senator GB (1986) Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201–995. Lancet 2: 574

    Article  PubMed  CAS  Google Scholar 

  • Tomura H, Okajima F, Akbar M, Abdul-Majid M, Sho K, Kondo Y (1994) Transfected human somatostatin receptor type 2, SSTR2, not only inhibits adenylate cyclase but also stimulates phospholipase C and Ca2+ mobilization. Biochem Biophys Res Commun 200:986–992

    Article  PubMed  CAS  Google Scholar 

  • Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S (1995) Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumors and renal cell carcinoma. J Clin Endocrinol Metab 80: 2974–2979

    Article  PubMed  CAS  Google Scholar 

  • Wiedenmann B, Rath U, Radsch R, Becker F, Kommereil B (1988) Tumour regression of an ileal carcinoid under treatment with the somatostatin analogue SMS 201–995. Klin Wochenschr 66: 75–77

    Article  PubMed  CAS  Google Scholar 

  • Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann HC (1998) Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 28: 1038–1049

    Article  PubMed  CAS  Google Scholar 

  • Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L et al (1998] Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci USA 95:10836

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Endocrinology, Department of Medicine, Philipps-University of Marburg, Baldingerstrasse, 35033, Marburg, Germany

    H.-C. Fehmann, U. Wulbrand & R. Arnold

Authors
  1. H.-C. Fehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Wulbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin, Innere Medizin II (Hämatologie, Onkologie, Endokrinologie, Stoffwechselerkrankungen), Klinikum der Friedrich-Schiller-Uniersität Jena, Erlanger Allee 101, D-00740, Jena, Germany

    Klaus Höffken  & Roland Kath  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin · Heidelberg

About this paper

Cite this paper

Fehmann, HC., Wulbrand, U., Arnold, R. (2000). Treatment of Endocrine Gastroenteropancreatic Tumors with Somatostatin Analogues. In: Höffken, K., Kath, R. (eds) Peptides in Oncology III. Recent Results in Cancer Research, vol 153. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59587-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59587-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64038-4

  • Online ISBN: 978-3-642-59587-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation